Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Cancer genomics

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44338   clinical trials with a EudraCT protocol, of which   7368   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    50 result(s) found for: Cancer genomics. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2017-003684-35 Sponsor Protocol Number: R2810-ONC-1763 Start Date*: 2018-07-10
    Sponsor Name:Regeneron Pharmaceuticals, Inc.
    Full Title: A Randomized, Open-Label Study of Combinations of Standard and High Dose REGN2810 (Cemiplimab; Anti-PD-1 Antibody) and Ipilimumab (Anti-CTLA-4 Antibody) in the Second-Line Treatment of Patients wit...
    Medical condition: Non-Small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004864 10025048 Lung cancer non-small cell recurrent LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) GB (GB - no longer in EU/EEA) FR (Completed) PL (Completed) ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2015-004860-12 Sponsor Protocol Number: ERCAVATAR2015 Start Date*: 2016-02-24
    Sponsor Name:Centro Nacional Investigaciones Oncológicas (CNIO)
    Full Title: Integrated Genomics and Avatar Mouse Models for Personalized Treatment of Pancreatic Cancer
    Medical condition: Metastatic pancreatic cancer
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033610 Pancreatic carcinoma metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-004603-35 Sponsor Protocol Number: REACH Start Date*: 2009-04-28
    Sponsor Name:University of Heidelberg
    Full Title: Radiotherapy (IMRT), Erbitux And Chemotherapy For Unresectable Carcinomas Of Head and Neck. REACH-Study
    Medical condition: Histologically confirmed locally advanced (stage III or IV), non-metastatic squamous cell carcinoma of oro-, hypopharynx or larynx (T2-4, NX, M0).
    Disease: Version SOC Term Classification Code Term Level
    9.1 10041849 Squamous cell carcinoma of the hypopharynx LLT
    9.1 10023856 Laryngeal squamous cell carcinoma LLT
    9.1 10031112 Oropharyngeal squamous cell carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-000476-26 Sponsor Protocol Number: N14DAR Start Date*: 2020-07-13
    Sponsor Name:Netherlands Cancer Institute
    Full Title: Dynamics of Androgen Receptor genomics and transcriptomics after neoadjuvant androgen ablation (DARANA)
    Medical condition: Prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036920 Prostate cancer stage IV PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036911 Prostate cancer recurrent PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036912 Prostate cancer stage 0 PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036917 Prostate cancer stage I PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036919 Prostate cancer stage III PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036918 Prostate cancer stage II PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-007943-29 Sponsor Protocol Number: EFC6521 Start Date*: 2008-07-29
    Sponsor Name:sanofi-aventis recherche & développement
    Full Title: A multinational, randomized, double blind, placebo-controlled study to evaluate the efficacy and safety of AVE5026 in the prevention of venous thromboembolism (VTE) in cancer patients at high risk ...
    Medical condition: The subjects who will participate to this clinical trial are cancer patients (i.e. patients with metastatic or locally advanced tumor of the lung, pancreas, stomach, colon/ rectum, bladder or ovary...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) FR (Completed) AT (Completed) LV (Completed) EE (Completed) SE (Completed) SK (Completed) NL (Completed) PT (Completed) LT (Completed) BE (Completed) DK (Completed) CZ (Completed) FI (Completed) SI (Completed) IT (Completed) BG (Completed) ES (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2018-000469-35 Sponsor Protocol Number: CL03-ORY-1001SCLC Start Date*: 2018-10-10
    Sponsor Name:Oryzon Genomics S. A.
    Full Title: A pilot study to assess the safety, tolerability, dose finding and efficacy ORY-1001 in combination with platinum-etoposide chemotherapy in patients with relapsed, extensive-stage disease small cel...
    Medical condition: Relapsed, extended-stage disease small cell lung cancer (ED SCLC).
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10041071 Small cell lung cancer stage unspecified LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2014-000809-12 Sponsor Protocol Number: PREDIXLumA Start Date*: 2014-11-17
    Sponsor Name:Karolinska University Hospital
    Full Title: PREDIX Luminal A - Neoadjuvant response-guided treatment of slowly proliferating hormone receptor positive tumors. Part of a set of translational phase II trials based on molecular subtypes
    Medical condition: Primary breast cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006200 Breast cancer stage II PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006201 Breast cancer stage III PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006191 Breast cancer male NOS LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006188 Breast cancer female NOS LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2012-000167-25 Sponsor Protocol Number: UC-0110/1201 Start Date*: 2012-05-29
    Sponsor Name:UNICANCER
    Full Title: A multicentric randomized phase II study evaluating dual targeting of the EGFR using the combination of cetuximab and afatinib versus cetuximab alone in patients with chemotherapy refractory wtKRAS...
    Medical condition: Refractory wtKRAS metastatic colorectal cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2016-001321-14 Sponsor Protocol Number: INCB54828-201 Start Date*: 2017-01-12
    Sponsor Name:Incyte Corporation
    Full Title: A Phase 2, Open-Label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FG...
    Medical condition: Subjects with metastatic or surgically unresectable urothelial cancer (may include primary site from ureters, upper tract, renal pelvis, and bladder) with an FGF/FGFR alteration, who failed at leas...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005003 Bladder cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) BE (Completed) FR (Completed) ES (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2007-002608-16 Sponsor Protocol Number: NVALT-8B Start Date*: 2009-07-13
    Sponsor Name:UMCG
    Full Title: A randomized phase III study of adjuvant chemotherapy with or without low-molecular weight heparin in patients with high risk for recurrence and completely resected non-small-cell lung cancer: NVAL...
    Medical condition: This is a randomized multicenter phase III study. Patient with a high SUVof the primary tumor prior to surgery will be randomised to four cycles of pemetrexed and cisplatin with or without nadropar...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-002644-21 Sponsor Protocol Number: NVALT-8A Start Date*: 2009-07-13
    Sponsor Name:UMCG
    Full Title: A randomized phase III study of adjuvant chemotherapy in patients with completely resected Non-Small-Cell Lung Cancer and low-risk for recurrence: NVALT-8A
    Medical condition: This is a randomized multicenter phase III study. Patient with a low SUV of the primary tumor prior to surgery will be randomised to four cycles of cisplatin-based chemotherapy or observation in a ...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-000482-36 Sponsor Protocol Number: CL02-ORY-1001AML Start Date*: 2018-09-07
    Sponsor Name:Oryzon Genomics S. A.
    Full Title: A pilot study to assess the safety, tolerability, dose finding and efficacy of ORY-1001 in combination with azacitidine in older patients with AML in first line therapy.
    Medical condition: Patients with acute mieloyd leukemia (AML)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004864 10024349 Leukemia myeloid LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2019-003192-18 Sponsor Protocol Number: NCT-PMO-1602 Start Date*: 2021-07-08
    Sponsor Name:German Cancer Research Center
    Full Title: Continuous ReAssessment with Flexible ExTension in Rare Malignancies – CRAFT: The NCT PMO-1602 Phase II Trial
    Medical condition: Metastatic or locally advanced malignancies
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065147 Malignant solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-000649-39 Sponsor Protocol Number: EMR62202-502 Start Date*: 2004-12-01
    Sponsor Name:Merck KGaA
    Full Title: A randomized, controlled, multicenter, phase I/II study of cetuximab plus irinotecan investigating the pharmacodynamics, genomics and -genetics as well as the safety and efficacy of a dose escalat...
    Medical condition: Metastatic colorectal cancer refractory to irinotecan treatment
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) AT (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-003298-24 Sponsor Protocol Number: R4018ONC1721 Start Date*: 2020-06-11
    Sponsor Name:Regeneron Pharmaceuticals, Inc.
    Full Title: A Phase 1/2 Study of REGN4018 (A MUC16xCD3 Bispecific Antibody) Administered Alone or in Combination with Cemiplimab in Patients with Recurrent Ovarian Cancer or Other Recurrent MUC16+ Cancers
    Medical condition: Recurrent Ovarian Cancer Recurrent Fallopian Tube Cancer Recurrent Primary Peritoneal Cancer Recurrent Endometrial Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066697 Ovarian cancer recurrent PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014736 Endometrial cancer recurrent PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Trial now transitioned) ES (Ongoing) NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-001309-22 Sponsor Protocol Number: 2593957 Start Date*: 2021-03-29
    Sponsor Name:IQVIA Commercial GmbH & Co. OHG
    Full Title: Evaluation of immunological effects of the hedgehog inhibitors on basal cell carcinoma - An open label, prospective, observational biomarker study of the DeCOG.
    Medical condition: Basal cell carcinoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10064679 Basal cell carcinoma of skin in situ LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2019-001908-38 Sponsor Protocol Number: R5093-ONC-1863 Start Date*: 2020-09-28
    Sponsor Name:Regeneron Pharmaceuticals, Inc.
    Full Title: A PHASE 1/2 STUDY OF REGN5093 IN PATIENTS WITH MET-ALTERED ADVANCED NON-SMALL CELL LUNG CANCER
    Medical condition: Non-small cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-000808-10 Sponsor Protocol Number: PREDIX-HER2 Start Date*: 2014-11-12
    Sponsor Name:Karolinska University Hospital
    Full Title: PREDIX HER2 - Neoadjuvant response-guided treatment of HER2 positive breast cancer. Part of a platform of translational phase II trials based on molecular subtypes
    Medical condition: Primary breast cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006200 Breast cancer stage II PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006201 Breast cancer stage III PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006191 Breast cancer male NOS LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006188 Breast cancer female NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-000987-80 Sponsor Protocol Number: ET19036 Start Date*: 2019-10-15
    Sponsor Name:Centre Léon Bérard
    Full Title: COTESARC - A multicentre Phase I-II study evaluating the combination of a MEK inhibitor and a PDL1 inhibitor in pediatric and adult patients with locally advanced and/or metastatic soft tissue sarc...
    Medical condition: advanced/metastatic soft tissu sarcoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10039491 Sarcoma PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-001455-32 Sponsor Protocol Number: WIN001 Start Date*: 2017-12-15
    Sponsor Name:Worldwide Innovative Network Association
    Full Title: A proof of concept study to explore safety and efficacy of tri-therapy approach in advanced/metastatic NSCLC and retrospectively assess the ability of integrated genomics and transcriptomics to mat...
    Medical condition: Patients with advanced/metastatic non-small cell lung cancer (NSCLC) with no documented targetable alterations (EGFR mutation, ALK translocation, ROS1 mutation if available or MET exon 14 skipping ...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended) ES (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 27 20:00:41 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA